Plaintiffs had argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

An over-the-counter medication sold today as Zantac 360 by Sanofi has a different active ingredient from the withdrawn versions of Zantac and has not raised questions about a cancer link.

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer.